162 related articles for article (PubMed ID: 19800446)
1. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats.
Laurenzana EM; Hendrickson HP; Carpenter D; Peterson EC; Gentry WB; West M; Che Y; Carroll FI; Owens SM
Vaccine; 2009 Nov; 27(50):7011-20. PubMed ID: 19800446
[TBL] [Abstract][Full Text] [Related]
2. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.
Hambuchen MD; Rüedi-Bettschen D; Gunnell MG; Hendrickson H; Owens SM
Hum Vaccin Immunother; 2016 Sep; 12(9):2240-8. PubMed ID: 27163775
[TBL] [Abstract][Full Text] [Related]
3. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.
White SJ; Hendrickson HP; Atchley WT; Laurenzana EM; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2014 Aug; 42(8):1285-91. PubMed ID: 24839971
[TBL] [Abstract][Full Text] [Related]
4. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.
Hambuchen MD; Rüedi-Bettschen D; Williams DK; Hendrickson H; Owens SM
Vaccine; 2014 Oct; 32(47):6213-9. PubMed ID: 25252196
[TBL] [Abstract][Full Text] [Related]
5. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.
Laurenzana EM; Byrnes-Blake KA; Milesi-Hallé A; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2003 Nov; 31(11):1320-6. PubMed ID: 14570763
[TBL] [Abstract][Full Text] [Related]
6. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse.
Peterson EC; Gunnell M; Che Y; Goforth RL; Carroll FI; Henry R; Liu H; Owens SM
J Pharmacol Exp Ther; 2007 Jul; 322(1):30-9. PubMed ID: 17452421
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats.
Byrnes-Blake KA; Laurenzana EM; Carroll FI; Abraham P; Gentry WB; Landes RD; Owens SM
Eur J Pharmacol; 2003 Feb; 461(2-3):119-28. PubMed ID: 12586207
[TBL] [Abstract][Full Text] [Related]
9. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.
Peterson EC; Laurenzana EM; Atchley WT; Hendrickson HP; Owens SM
J Pharmacol Exp Ther; 2008 Apr; 325(1):124-33. PubMed ID: 18192498
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody.
McMillan DE; Hardwick WC; Li M; Owens SM
Behav Pharmacol; 2002 Sep; 13(5-6):465-73. PubMed ID: 12394422
[TBL] [Abstract][Full Text] [Related]
11. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food.
Rüedi-Bettschen D; Wood SL; Gunnell MG; West CM; Pidaparthi RR; Carroll FI; Blough BE; Owens SM
Vaccine; 2013 Sep; 31(41):4596-602. PubMed ID: 23906885
[TBL] [Abstract][Full Text] [Related]
12. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat.
McMillan DE; Hardwick WC; Li M; Gunnell MG; Carroll FI; Abraham P; Owens SM
J Pharmacol Exp Ther; 2004 Jun; 309(3):1248-55. PubMed ID: 14993256
[TBL] [Abstract][Full Text] [Related]
13. The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats.
Hubbard JJ; Laurenzana EM; Williams DK; Gentry WB; Owens SM
J Pharmacol Exp Ther; 2011 Feb; 336(2):414-22. PubMed ID: 20962030
[TBL] [Abstract][Full Text] [Related]
14. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction.
Gentry WB; Rüedi-Bettschen D; Owens SM
Clin Pharmacol Ther; 2010 Sep; 88(3):390-3. PubMed ID: 20668443
[TBL] [Abstract][Full Text] [Related]
15. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
[TBL] [Abstract][Full Text] [Related]
16. Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE.
Stevens MW; Rüedi-Bettschen D; Gunnell MG; Tawney R; West CM; Owens SM
Drug Alcohol Depend; 2019 Nov; 204():107484. PubMed ID: 31521953
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.
Owens SM; Atchley WT; Hambuchen MD; Peterson EC; Gentry WB
CNS Neurol Disord Drug Targets; 2011 Dec; 10(8):892-8. PubMed ID: 22229314
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
Gentry WB; Laurenzana EM; Williams DK; West JR; Berg RJ; Terlea T; Owens SM
Int Immunopharmacol; 2006 Jun; 6(6):968-77. PubMed ID: 16644483
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats.
Byrnes-Blake KA; Laurenzana EM; Landes RD; Gentry WB; Owens SM
Eur J Pharmacol; 2005 Oct; 521(1-3):86-94. PubMed ID: 16182279
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
